<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR45">
 <label>45.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Wang</surname>
    <given-names>XJ</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na(+)-dependent taurocholate cotransporting polypeptide activity</article-title>
  <source>Antivir. Res.</source>
  <year>2015</year>
  <volume>120</volume>
  <fpage>140</fpage>
  <lpage>146</lpage>
  <pub-id pub-id-type="doi">10.1016/j.antiviral.2015.06.007</pub-id>
  <?supplied-pmid 26086883?>
  <pub-id pub-id-type="pmid">26086883</pub-id>
 </element-citation>
</ref>
